{"id":"NCT02180659","sponsor":"Titan Pharmaceuticals","briefTitle":"A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants","officialTitle":"A Randomized, Double-Blind, Double-Dummy, Active-Controlled Multicenter Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily Maintenance Dose of 8 mg or Less of Sublingual Buprenorphine or Buprenorphine/Naloxone to Four Probuphine® Subdermal Implants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-07","primaryCompletion":"2015-05","completion":"2015-05","firstPosted":"2014-07-03","resultsPosted":"2018-12-05","lastUpdate":"2019-01-11"},"enrollment":177,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Opioid Dependence"],"interventions":[{"type":"DRUG","name":"sublingual buprenorphine tablets","otherNames":[]},{"type":"DRUG","name":"Buprenorphine implant","otherNames":[]},{"type":"DRUG","name":"placebo implants","otherNames":[]},{"type":"DRUG","name":"sublingual placebo tablets","otherNames":[]}],"arms":[{"label":"buprenorphine implants + placebo tablets","type":"EXPERIMENTAL"},{"label":"buprenorphine tablets + placebo implants","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of the study is to demonstrate maintenance of treatment efficacy when transferring adult outpatients with opioid dependence, who are clinically stabilized on 8 mg or less of sublingual (SL) buprenorphine (BPN), to 4 Probuphine implants compared to SL BPN.\n\nThe secondary objective of the study is to confirm safety of 4 Probuphine implants in adult outpatients with opioid dependence who are clinically stabilized on 8 mg or less of SL BPN.","primaryOutcome":{"measure":"The Primary Efficacy Endpoint is a Responder Rate Analysis, Where a Responder is Defined as a Patient With no More Than 2 of 6 Months With Any Evidence of Illicit Opioid Use.","timeFrame":"24 weeks","effectByArm":[{"arm":"Buprenorphine Implants + Placebo Tablets","deltaMin":81,"sd":null},{"arm":"Buprenorphine Tablets + Placebo Implants","deltaMin":78,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["27434441"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":87},"commonTop":["Muscle spasm","Abortion - Spontaneous","Pregnancy","Pediatric exposure to treatment","Cellulitis"]}}